Compare CYD & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | VIR |
|---|---|---|
| Founded | 1951 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1998 | 2019 |
| Metric | CYD | VIR |
|---|---|---|
| Price | $40.53 | $11.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $60.00 | $19.43 |
| AVG Volume (30 Days) | 108.5K | ★ 1.5M |
| Earning Date | 02-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $15.11 | $270.22 |
| Revenue Next Year | $8.67 | N/A |
| P/E Ratio | $32.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.65 | $4.75 |
| 52 Week High | $61.48 | $11.66 |
| Indicator | CYD | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 38.62 | 73.93 |
| Support Level | $37.24 | $8.43 |
| Resistance Level | $45.94 | $11.66 |
| Average True Range (ATR) | 1.84 | 0.51 |
| MACD | -0.59 | 0.25 |
| Stochastic Oscillator | 28.79 | 93.86 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.